Yonhap Infomax NewsSK Biopharmaceuticals has partnered with Boston-based Interon Laboratories to jointly develop an autism spectrum disorder drug candidate, expanding its R&D into neuroimmunology and advancing its Next CNS strategy.
#YonhapInfomax #SKBiopharmaceuticals #InteronLaboratories #AutismSpectrumDisorder #Neuroimmunology #JointResearchDevelopment #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=88799
#YonhapInfomax #SKBiopharmaceuticals #InteronLaboratories #AutismSpectrumDisorder #Neuroimmunology #JointResearchDevelopment #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=88799
SK Biopharmaceuticals Initiates Joint R&D with US-Based Interon on Autism Drug Candidate
SK Biopharmaceuticals has partnered with Boston-based Interon Laboratories to jointly develop an autism spectrum disorder drug candidate, expanding its R&D into neuroimmunology and advancing its Next CNS strategy.